Objective. To re-evaluate the roles of HLA-DRB1 alleles in susceptibility to SLE and RA and their effects on autoantibody status in large-scale Japanese cohorts.
Introduction
Genome-wide association studies for SLE and RA have discovered many disease susceptibility genes, where the strongest genetic link is seen in the HLA class II region for both diseases [13] . In European/Caucasian SLE patients, the HLA-DR3 serotype (or HLA-DRB1*03:01 for genotype) and DR2 (DRB1*15:01) have been associated with disease risk [1, 2, 4, 5] . In Asian populations, the association of DR2 was also replicated in many studies, while the exact role of each individual allele comprising the DR2 serotype (DRB1*15:01 and *15:02 are common in Asians) has not been established [610] . In addition, an association of DR9 (DRB1*09:01), which is rare in European populations, has been implicated in several Asian populations [68] , although it was not replicated in others [911] . This inconsistency may be due to the relatively small sample sizes examined in these individual studies, and it needs to be further tested.
In RA, the disease-associated DRB1 alleles (DR1/DR4/ DR10) are different among European populations but share a conserved amino acid motif (QKRAA/QRRAA/ RRRAA) at 7074, which are now referred to as the shared epitope (SE) [12, 13] . Since ACPA has been recognized in RA, a strong association between SE alleles and the appearance of ACPA has been described [1416] . Moreover, a geneenvironmental interaction between HLA-DRB1 and cigarette smoking was reported, showing that smokers who carry DRB1-SE alleles have a greater risk for the appearance of ACPA [1719] . In Asian populations, the association of SE alleles has also been repeatedly reported [18, 20] . In addition, DRB1*09:01, which is not classified as an SE allele, is another risk allele for RA in Asian populations, although the risk is moderate compared with that of SE alleles [18, 20] . The association between the appearance of ACPA and SE alleles has been replicated in Asian populations, but the effect of DRB1*09:01 on ACPA status is controversial [18, 2123] .
Another issue concerning the association of HLA-DRB1 alleles with diseases is the genotypic effects, including the gene dosage effect of each allele and the combinational effect of two different alleles. In SLE, compound heterozygotes of susceptible alleles (i.e. DR2/DR3) confer a remarkably increased risk [1] . In European RA patients, compound heterozygotes of SE alleles (i.e. DRB1*04:01/ *04:04) are significantly associated with severe disease in comparison with the homozygotes [24, 25] . In Asia, a study on Koreans demonstrated that the DRB1*04:05/ *09:01 heterozygote conferred a stronger risk for RA than the homozygote for DRB1*04:05 [26] .
Here, to examine and refine the previous findings described so far, we investigated the associations of HLA-DRB1 alleles with a predisposition to SLE and RA in a Japanese population using a large cohort composed of 656 SLE, 2410 RA and 911 control subjects. We also explored the effect of DRB1 alleles on disease sub-phenotypes by examining the association between DRB1 genotypes and autoantibody production in the patients. [27] and the Midosuji Rotary Club for the controls. All 656 SLE subjects fulfilled the 1997 revised criteria of the ACR for SLE [28] , and the RA subjects met the 1987 revised criteria of ACR for RA [29] . The control subjects were the same as those used in a previous study [30] . Subjects having a history of autoimmune diseases were excluded from control subjects based on a questionnaire. All subjects were Japanese and provided informed consent to participate in the study. The study was approved by the ethical committee of each institute (RIKEN Institute, University of Tokyo, Tohoku University, Hokkaido University, University of Occupational and Environmental Health, Wakayama Medical University, Keio University, University of Tsukuba, Juntendo University and Kyoto University).
Patients and methods

Subjects
Genotyping of HLA-DRB1
High-resolution (four-digit) genotyping of HLA-DRB1 was performed by a sequence-specific PCR method with a WAKFlow HLA typing kit (Wakunaga, Hiroshima, Japan) and a Luminex multi-analyte profiling system (xMAP; Luminex, Austin, TX), according to the manufacturer's instructions. For the analysis of RA patients, DRB1 alleles that contained amino acid sequences QKRAA/QRRAA/ RRRAA at 7074 were classified as SE+.
Autoantibody and smoking status
Clinical data for 562 SLE subjects (85.7%) were available. All individual ACR criteria were coded as positive, negative or missing. For the study of SLE patients, we obtained autoantibody status from these clinical data, including anti-dsDNA antibody, anti-Sm antibody, aCL and lupus anticoagulant (LAC). The number of subjects available for autoantibody status and the positivity rate for each autoantibody were as follows: anti-dsDNA, n = 541, 91.7%; anti-Sm, n = 451, 35.5%; anti-CL, n = 419, 33.9%; LAC, n = 349, 21.2%. All these autoantibodies except for LAC were examined by ELISA. LAC was detected by activated partial thromboplastin time and dilute Russell viper venom time according to the international guideline [31] .
Sera from 2384 RA patients (98.9%) were available for the measurement of ACPA. ACPA was measured using the Mesacup CCP test (Medical and Biological Laboratories, Woburn, MA). The positivity rate of ACPA was 79.0%. Smoking status was available for 2294 patients (95.2%) and smoking rates were a total of 32.7%; male www.rheumatology.oxfordjournals.org 82.2% and female 21.2%. The data were recorded as ever or never smoker. Ever smokers contained former and current smokers.
Statistical analysis
We performed logistic regression analyses in casecontrol studies to adjust for sex and age. In case-only analyses, we tested the association by the standard 2 test using 2 Â 2 contingency tables. Fisher's exact test was applied when a cell value was <5. Only alleles with frequencies >0.01 in control samples were analysed, and Bonferroni's correction was applied for multiple testing (20 tests, a = 0.0025). The contingency tables were used to calculate the odds ratio (OR). Disease association was also assessed by the relative predispositional effect (RPE) [32] . When the disease is associated with two or more alleles of a locus, this method identifies the associations sequentially according to their strength. Thus the problem that a strong association with one allele can create misleading deviations in the frequencies of other alleles is alleviated. In the RPE analysis of RA, all the SE-carrying alleles were treated as a single SE allele. We calculated population-attributable risk (PAR) using the following formula:
where f is the allele frequency. The mean age at disease onset was analysed by the MannWhitney U test. To evaluate a multiplicative interaction between alleles, we introduced the interaction term in a logistic regression model [19, 3335] . We also evaluated the interaction by calculating three measures, including the relative excess risk due to interaction (RERI), the proportion attributable to interaction (AP) and the synergy index (S) [36] . We performed k-means cluster analysis to identify cluster groups of SLE patients with similar autoantibody patterns using the clinical data of anti-dsDNA, anti-Sm and anti-CL autoantibodies and LAC, as previously described [37] . We replaced missing data with the mean positive rate of each autoantibody in order to maximize the statistical power [34] . Then we compared autoantibody status and DRB1 allele frequency among the three groups by 2 test using 2 Â 3 tables. All statistical analyses were performed using STATISTICA (StatSoft, Tulsa, OK).
Results
Distribution of HLA-DRB1 alleles in SLE and RA
The allele distribution of HLA-DRB1 in SLE, RA and control subjects is presented in Table 1 . In SLE, only DRB1*15:01 showed a significant association with disease susceptibility (P = 4.2 Â 10 À9 , OR 2.90). In the RPE analysis, DRB1*04:01, *08:02 and *09:01 were significantly associated with SLE susceptibility (P < 0.0025). As DRB1*15:01, *08:02 and *09:01 were the three prominent alleles in our population showing a strong association with SLE and a substantial extent of PAR (0.117, 0.032 and 0.063, respectively), we focused on the DRB1*15:01, *08:02 and *09:01 alleles for further analysis of SLE.
In RA, SE alleles, including DRB1*04:01 and *04:05, displayed significant association with disease (P < 0.0025), and DRB1*04:05 showed the highest risk (P = 4.9 Â
10
À22 , OR 2.59). When we evaluated SE alleles collectively, they contributed to a substantial proportion of the RA risk when evaluated by PAR (= 0.233). After SE alleles were excluded collectively in the RPE analysis, only DRB1*09:01 was significantly associated with RA susceptibility (P = 3.8 Â 10 À8 ). Thereafter we focused on SE alleles and DRB1*09:01 for further analysis of RA.
Genotypic association analyses of HLA-DRB1 with disease susceptibility
To analyse the combinational effect of the three major risk alleles of SLE, we grouped the SLE patients by the presence of DRB1*08:02, *09:01 and *15:01 alleles (Table 2) . When compared with the reference genotype (denoted as X/X in SLE), the homozygote DRB1*09:01/*09:01 showed a greater risk (OR 2.37) than the heterozygote DRB1*09:01/X (OR 1.48), which implied the presence of a gene dosage effect. In contrast, no obvious gene dosage effect was seen in DRB1*15:01, although a lack of statistical power was undeniable. Strikingly, the compound heterozygote DRB1*09:01/*15:01 conferred the highest risk for SLE (OR 7.42). The heterozygote DRB1*09:01/*15:01 showed a significantly increased risk for SLE in comparison with the homozygote for DRB1*09:01 (P = 0.0076, OR 5.05), while no significant difference was observed between the compound heterozygote and the homozygote for DRB1*15:01 (P = 0.52, OR 2.13), in which there was a lack of statistical power. When the multiplicative interaction between DRB1*15:01 and *09:01 was evaluated in a logistic regression model, the coefficient for the interaction term was not significant but marginal (P = 0.078). However, the three measures for interaction as departures from additivity suggested a possible interaction [RERI 6.17 (95% CI À2.04, 14.38), AP 0.63 (95% CI 0.31, 0.96), S 3.39 (95% CI 1.22, 9.48)].
In the RA cohort, we grouped the patients by the presence of DRB1-SE and *09:01 (Table 2 ). In comparison with heterozygote SE/Y, homozygote SE/SE showed a significantly increased risk (P = 1.1 Â 10 À6 , OR 2.69), which confirmed the gene dosage effect of SE alleles as previously described [24] . The homozygote of DRB1*09:01 suggested a moderately increased risk for RA compared with the heterozygote (P = 0.093, OR 1.69). As the risk of compound heterozygote SE/*09:01 did not significantly exceed the risk of homozygote SE/SE nor *09:01/*09:01, there was no dominant compound effect (data not shown). Likewise, no compound effect was detected in *0405/*0901 (data not shown), unlike the previous report in a Korean population [26] .
In addition to analysing the genotypic effect of HLA-DRB1 on disease susceptibility, we also analysed its effect on the age of disease onset. Among the genotypes of SLE patients, only the compound heterozygote DRB1*09:01/*15:01 conferred a significantly earlier onset of SLE when compared with X/X (24.3 vs 30.9 years, P = 4.3 Â 10 À4 ) ( Table 3 ). The same result was obtained when only female patients were analysed. In RA, the homozygote SE/SE and the compound heterozygote SE/*09:01 were significantly associated with an earlier , respectively) ( Table 3) .
Association between DRB1 and autoantibody profile in SLE
Next we examined the difference in autoantibody status between genotypes in SLE patients. Considering that the number of homozygotic patients for DRB1*08:02, *09:01 and *15:01 was small, a dominant genetic model was used for this analysis. The DRB1*09:01-bearing genotypes (*09:01/*09:01 or *09:01/X) showed a significant risk for anti-Sm (P = 0.0084, OR 1.93), while it showed a protective effect for anti-dsDNA (P = 0.0014, OR 0.30) ( Table 4) . No significant association with autoantibody status was observed for either DRB1*15:01-bearing genotypes or the DRB1*09:01/*15:01 heterozygote, although a lack of statistical power was likely. The relationship observed between DRB1*09:01 and the status of anti-dsDNA and anti-Sm in the SLE patients prompted us to test whether HLA-DRB1 affected the autoantibody profiles in SLE. Previously To et al. [37] performed a cluster analysis of the autoantibody profiles in European SLE patients and showed that SLE patients could be divided into three distinct clusters: cluster A (anti-Sm and anti-RNP), cluster B (anti-dsDNA, anti-Ro and anti-La) and cluster C (anti-dsDNA, aCL and LAC). Cluster A showed a significantly higher positive rate of anti-Sm antibody and a lower rate of anti-dsDNA antibody than the two other clusters. Therefore we speculated that Japanese SLE patients could also be sub-clustered by autoantibody profiles, where DRB1 alleles could be involved. We performed k-mean cluster analysis using autoantibody profiles containing anti-dsDNA, anti-Sm antibodies, aCL and LAC. Similar to the results reported, we found three distinct autoantibody clusters (Table 5 ). The prevalence of each autoantibody was statistically different among clusters, except for the anti-dsDNA antibody for which the difference was marginal. Then we compared each allele frequency of DRB1*08:02, *09:01 and *15:01 among the three clusters and found that the frequency of DRB1*09:01 significantly differed among the clusters (P = 0.010). In Cluster 1, characterized by a higher positivity rate of anti-Sm and a lower rate of anti-dsDNA, a higher allele frequency of DRB1*09:01 and lower frequency of DRB1*15:01 were observed as compared with the other clusters. The allele frequency of DRB1*09:01 in Cluster 1 was significantly higher than that of Clusters 2 and 3 (P = 0.0027 and 0.035 by 2 tests, respectively) ( Table 5 ). The approach of replacing missing data with the mean positive rate is one of the established methods [34] , but might lead to false-positive findings. Therefore we also performed k-mean cluster analysis based on casewise deletion and identified similar cluster groups and DRB1*09:01 frequency distributions among the groups. However, the difference of allele frequencies among the clusters was marginal (P = 0.09), suggesting that validation studies using larger sample sizes would be required.
Association of DRB1 and ACPA status in RA and its interaction with smoking
We evaluated the association of DRB1-SE alleles as well as DRB1*09:01 with ACPA status in our population. When genotype frequencies of DRB1 were compared between ACPA-positive RA patients (n = 1884) and negative patients (n = 501), the SE-bearing genotypes (SE/SE or SE/ Y) as well as *09:01-bearing genotypes (*09:01/*09:01 or *09:01/Y) conferred significantly increased risk of the appearance of ACPA ( www.rheumatology.oxfordjournals.org *09:01 vs *09:01/Y, P = 0.27, OR 1.38). There was no obvious dominant compound effect in neither SE/*09:01 nor *04:05/*09:01 (data not shown). Next, we assessed geneenvironment interactions between smoking and SE or DRB1*09:01 alleles in developing ACPA. A larger effect on ACPA development was observed in ever smokers than in never smokers, when patients carried double SE alleles (double SE/ever smoker: OR 13.74; double SE/never smoker: OR 6.77) ( Table 6 ). In order to investigate the interactions between smoking and SE or DRB1*09:01, we examined the interaction terms in a logistic regression model. The logistic coefficient for the interaction term between SE and smoking was significant (P = 0.047). However, that between DRB1*09:01 and smoking was not significant (P = 0.34), although lack of statistical power should be considered. 
Discussion
In the present analysis of HLA-DRB1 locus in Japanese SLE and RA patients using one of the largest cohorts ever examined in Asian populations, we demonstrated that DRB1 alleles were associated with susceptibility as well as disease subphenotype, where the DRB1*09:01 allele, prominent in Asian populations, has a significant impact in both diseases. In SLE, HLA-DRB1*15:01, *09:01, *08:02 and *04:01 were significantly associated with disease susceptibility in our population, where the association of *08:02 and *04:01 has not been previously described in Asian populations. In contrast to *15:01, we did not observe a significant association in DRB1*15:02. As the *15:02 allele is rarely observed in European populations, and the majority of previous studies in Asian populations examined these alleles together as DR2 (or DR15) serotypes, the differential role of these two alleles had not been clearly defined. As for the amino acid sequence, these alleles only differ at position 86 (a valine for DRB1*15:01 and a glycine for DRB1*15:02). This amino acid constitutes the P1 pocket of the DRb molecule and is considered to be critical for antigen presentation [38] . The influence of other HLA genes on the haplotype of DRB1, such as DQB1, should also be considered. In this context, the positive association of DRB1*15:02 observed in Taiwanese and Thais [39, 40] , unlike in our population, could be explained by the primary association of DQB1*05:01, considering that the DRB1*15:02 is in strong linkage disequilibrium with DQB1*06:01, not with DQB1*05:01, in a Japanese population.
In the genotypic comparison, we found that the compound heterozygote DRB1*09:01/*15:01 showed a remarkable contribution to increased risk of SLE as well as earlier disease onset. A compound heterozygote of DRB1 haplotypes may have an increased probability of presenting self-antigens, leading to increased predisposition and earlier onset of disease. Alternatively, the transcomplementing heterodimers formed by DQA and DQB genes on the haplotype of DRB1*09:01 and *15:01 could also explain the increased effect of heterozygote, as was suggested in a study of Type 1 diabetes (T1D) [41] . In contrast to SLE, no obvious compound heterozygote effect of DRB1-SE/*09:01 (or *04:05/*09:01) was observed in RA, possibly because the stronger effect of SE alleles may dominate that of DRB1*09:01 in RA.
We demonstrated a positive association of DRB1*09:01 with anti-Sm antibody formation, but a negative association with anti-dsDNA antibody in SLE patients, implying that differential mechanisms involving different DR molecules underlie the appearance of these autoantibodies. A recent study in European patients reported that an SNP in the HLA class II region was associated with anti-dsDNA antibody-negative patients, which may support our findings [42] . To et al. [37] found that SLE patients could be grouped into several autoantibody patterns, and one of the groups was characterized by a higher positivity rate of anti-RNP and anti-Sm and a lower rate of anti-dsDNA antibodies. This grouping by autoantibody patterns was also applicable to the population we examined. In addition, as differential distribution of DRB1 alleles was also observed among the groups in our population, combinations of the class II haplotypes should affect autoantibody production in SLE and may influence clinical subphenotypes of SLE patients.
The association of SE alleles in ACPA-positive RA has been well established in both European and Asian populations [1416, 18, 19] . This suggests an essential role of the SE alleles in presenting citrullinated self-antigens. In addition, a geneenvironment interaction between SE alleles and smoking has been demonstrated for the onset of RA [18, 19] . These suggest a pathological series of smoking, citrullination of self-proteins and antigen presentation by SE alleles [43] . However, whether this is also the case for DRB1*09:01 is not clear. Two previous studies in Japanese populations suggested that DRB1*09:01 but not SE alleles is associated with ACPA-negative RA [21, 22] . The study by Furuya et al. [21] indicated a significant association of DRB1*09:01 with ACPA-negative RA (P = 0.016, OR 2.2). Another study by Terao et al. [22] , in which the ACPA-negative patients (502 subjects) used in the present study were also included, showed a marginal association with ACPA-negative RA (P = 0.062, OR 1.16). However, the effect of DRB1*09:01, independent of SE alleles, on ACPA-positive RA was not evaluated in these studies. Another study in a Korean population showed that DRB1*09:01 made a significant contribution to the appearance of ACPA independently of SE (P = 1.10 Â 10 À3 , OR 2.49) [18] , which corresponds to our observation (Table 6 ). Taken together, this evidence suggests that DRB1*09:01 confers risk for both ACPA-positive and ACPA-negative RA. Moreover, as no significant geneenvironmental interaction was observed between smoking and DRB1*09:01 for the appearance of ACPA, DRB1*09:01 may not function in the same pathological series of SE alleles, as mentioned.
The amino acid sequence of DRB1*09:01 at 7074 (RRRAE) is different from that of the SE alleles. As both DRB1*14:05 and *14:54, the only alleles that share the RRRAE epitope in the Japanese population, displayed a negative trend for the risk of RA, it may be unlikely that this epitope alone can explain the susceptibility of DRB1*09:01 to RA. A recent study examining all possible epitopes in the DR molecule showed that two new epitopes (VH 11, 13 and LA 67,74 ) in addition to the classical SE exhibited a predisposition to RA in European populations [44] . Haplotypes involving DRB1*09:01 have been reported to be associated with autoimmune diseases other than RA and SLE, including T1D, Graves' disease, www.rheumatology.oxfordjournals.org mixed CTD and microscopic polyangiitis in Asian populations [4548] , suggesting that these autoimmune diseases share the same pathological pathway. Although the DR9 molecule itself may play an important role in disease pathogenesis, it is also known that DRB1*09:01 is in linkage with DRB4, a paralogue of DRB1 that also encodes DRb chains. DRB4 is only present in haplotypes of DRB1*04, *07 and *09. Its presence has been found to be associated with the progression of RA [49] and the presence of ACPA [50] . Therefore the association of DRB1*09:01 could be secondary to the effect of DRB4 in RA. In addition, the exclusive presence of DRB4 in DRB1*04 among SE alleles might explain the difference in the effect size between DRB1*04 alleles and other SE alleles (i.e. *01:01).
In conclusion, we identified HLA-DRB1 alleles associated with SLE and RA in a Japanese population and demonstrated a shared susceptibility of DRB1*09:01 between the diseases as well as its effect on autoantibody production. Further studies, such as structural analysis of the DRB1*09:01 product itself and analysis of other candidate causal variants of the DRB1*09:01 haplotype, are needed to clarify the exact role of the DRB1*09:01 haplotype in disease pathogenesis.
Rheumatology key messages
. A large-scale association study identified HLA-DRB1 alleles associated with SLE and RA in the Japanese population. . HLA-DRB1*09:01 allele is associated with susceptibility to both SLE and RA in the Japanese population. . HLA-DRB1*09:01 allele affects autoantibody profiles of SLE and RA in Japanese patients.
